Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Aptevo Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rituximab

            Therapeutic Area: Oncology Product Name: Ruxience

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Piper Sandler

            Deal Size: $11.0 million Upfront Cash: Undisclosed

            Deal Type: Divestment July 21, 2020

            Details:

            Aptevo is entitled to receive low single digit royalty payments from Pfizer Inc. pertaining to the net sales of RUXIENCE in the United States, European Union, and Japan. The royalty term runs for seven years, until early 2027, and payments are due quarterly.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rituximab

            Therapeutic Area: Oncology Product Name: Ruxience

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Financing June 25, 2020

            Details:

            This collection relates to the Company's sale of its Hemophilia B therapy, IXINITY®, to Medexus Pharmaceuticals.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recombinant coagulation factor IX

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: MEDEXUS INC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition May 22, 2020

            Details:

            The revenues from IXINITY® for March 2020 are in line with the Company’s expectations, including that the majority of the quarterly revenue from IXINITY® would be recognized in the final month of Q4 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APVO436

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2020

            Details:

            Dosing in cohorts 1 through 5 has been completed with dosing in cohort 6 scheduled to begin shortly.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Recombinant coagulation factor IX

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: MEDEXUS INC

            Deal Size: $30.0 million Upfront Cash: $30.0 million

            Deal Type: Acquisition February 28, 2020

            Details:

            Acquisition strengthens Medexus’ specialty product portfolio and represents a strategic fit with other products in the Medexus business development pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APVO436

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            APVO436 is a new investigational AML therapeutic, selected for an ongoing national AML master clinical trial spearheaded by The Leukemia & Lymphoma Society called the ‘Beat AML Master Clinical Trial.